| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 21 | 2025 | 1075 | 3.430 |
Why?
|
| Artificial Intelligence | 10 | 2025 | 357 | 2.870 |
Why?
|
| Medical Oncology | 6 | 2024 | 393 | 2.600 |
Why?
|
| Neoplasms | 16 | 2024 | 3114 | 2.060 |
Why?
|
| Papillomavirus Infections | 6 | 2025 | 274 | 1.830 |
Why?
|
| Salivary Gland Neoplasms | 8 | 2025 | 77 | 1.570 |
Why?
|
| Carcinoma, Adenoid Cystic | 7 | 2025 | 41 | 1.430 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2024 | 1091 | 1.370 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2024 | 127 | 1.360 |
Why?
|
| Neoplastic Stem Cells | 10 | 2021 | 167 | 1.360 |
Why?
|
| Humans | 96 | 2025 | 92175 | 0.970 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2024 | 1266 | 0.970 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 2556 | 0.860 |
Why?
|
| Mouth Neoplasms | 5 | 2024 | 199 | 0.860 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1575 | 0.850 |
Why?
|
| Hematology | 1 | 2023 | 30 | 0.840 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 6 | 0.820 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 787 | 0.810 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1138 | 0.800 |
Why?
|
| Lenses | 1 | 2022 | 5 | 0.790 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 622 | 0.790 |
Why?
|
| Carcinoma | 2 | 2022 | 438 | 0.770 |
Why?
|
| Medicine | 1 | 2022 | 95 | 0.750 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2023 | 177 | 0.750 |
Why?
|
| Lens, Crystalline | 1 | 2022 | 69 | 0.740 |
Why?
|
| Papillomaviridae | 4 | 2025 | 165 | 0.740 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 64 | 0.710 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.710 |
Why?
|
| Specimen Handling | 1 | 2021 | 103 | 0.700 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 1310 | 0.700 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 17 | 0.700 |
Why?
|
| Academies and Institutes | 1 | 2020 | 33 | 0.700 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 37 | 0.700 |
Why?
|
| Microsatellite Instability | 4 | 2021 | 56 | 0.680 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 8 | 0.660 |
Why?
|
| ras Proteins | 1 | 2020 | 133 | 0.660 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 154 | 0.650 |
Why?
|
| Cyclin D1 | 1 | 2019 | 84 | 0.640 |
Why?
|
| Cell Proliferation | 10 | 2025 | 1720 | 0.640 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 303 | 0.640 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 1191 | 0.630 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2393 | 0.620 |
Why?
|
| Leadership | 1 | 2020 | 146 | 0.610 |
Why?
|
| Genomics | 1 | 2024 | 804 | 0.610 |
Why?
|
| Machine Learning | 7 | 2023 | 292 | 0.610 |
Why?
|
| Cell Line, Tumor | 20 | 2025 | 2667 | 0.590 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 3053 | 0.580 |
Why?
|
| Neoplasm Staging | 7 | 2022 | 2034 | 0.570 |
Why?
|
| Carcinoma, Mucoepidermoid | 4 | 2019 | 16 | 0.560 |
Why?
|
| Algorithms | 7 | 2024 | 1948 | 0.540 |
Why?
|
| Patient Selection | 1 | 2020 | 688 | 0.530 |
Why?
|
| Precision Medicine | 1 | 2021 | 425 | 0.530 |
Why?
|
| Mutation | 7 | 2024 | 4199 | 0.530 |
Why?
|
| Transcriptome | 2 | 2021 | 695 | 0.520 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 433 | 0.510 |
Why?
|
| Antineoplastic Agents | 9 | 2023 | 2368 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 12 | 2025 | 502 | 0.480 |
Why?
|
| Female | 40 | 2025 | 47822 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2024 | 1397 | 0.450 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 260 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2018 | 32 | 0.410 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 400 | 0.400 |
Why?
|
| Mice | 25 | 2025 | 12103 | 0.390 |
Why?
|
| Interleukin-6 | 3 | 2020 | 272 | 0.390 |
Why?
|
| Prognosis | 8 | 2023 | 3861 | 0.360 |
Why?
|
| Immunotherapy | 9 | 2023 | 724 | 0.360 |
Why?
|
| Tumor Burden | 4 | 2022 | 314 | 0.350 |
Why?
|
| Neoplasm Metastasis | 4 | 2024 | 1071 | 0.350 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 297 | 0.350 |
Why?
|
| Colorectal Neoplasms | 4 | 2024 | 1044 | 0.340 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 520 | 0.330 |
Why?
|
| Paclitaxel | 6 | 2025 | 495 | 0.320 |
Why?
|
| Middle Aged | 23 | 2025 | 27001 | 0.320 |
Why?
|
| Computational Biology | 2 | 2024 | 562 | 0.320 |
Why?
|
| Chemoradiotherapy | 4 | 2025 | 318 | 0.310 |
Why?
|
| Animals | 28 | 2025 | 27974 | 0.300 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 390 | 0.300 |
Why?
|
| Models, Biological | 3 | 2022 | 1784 | 0.290 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 150 | 0.290 |
Why?
|
| Male | 23 | 2025 | 43858 | 0.280 |
Why?
|
| Cisplatin | 6 | 2022 | 602 | 0.280 |
Why?
|
| Mice, SCID | 6 | 2018 | 263 | 0.280 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 332 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2017 | 17 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2017 | 33 | 0.260 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 286 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 429 | 0.260 |
Why?
|
| Signal Transduction | 8 | 2024 | 3508 | 0.250 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1476 | 0.240 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 22 | 0.230 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 547 | 0.230 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 18 | 0.230 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 438 | 0.230 |
Why?
|
| Quantum Theory | 1 | 2024 | 38 | 0.220 |
Why?
|
| Computers | 1 | 2024 | 111 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 873 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 76 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 976 | 0.210 |
Why?
|
| Quinolones | 1 | 2024 | 57 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 364 | 0.210 |
Why?
|
| Xerostomia | 1 | 2023 | 10 | 0.210 |
Why?
|
| DNA, Mitochondrial | 2 | 2024 | 189 | 0.210 |
Why?
|
| Mouth Diseases | 1 | 2023 | 15 | 0.210 |
Why?
|
| Oral Medicine | 1 | 2023 | 4 | 0.210 |
Why?
|
| Piperazines | 3 | 2019 | 288 | 0.200 |
Why?
|
| Drug Design | 1 | 2023 | 130 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2021 | 2972 | 0.200 |
Why?
|
| Aged | 13 | 2025 | 19915 | 0.200 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.200 |
Why?
|
| Pyridines | 3 | 2019 | 310 | 0.200 |
Why?
|
| Carboplatin | 4 | 2025 | 321 | 0.200 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 318 | 0.200 |
Why?
|
| Uncertainty | 1 | 2022 | 76 | 0.200 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 139 | 0.190 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 6 | 0.190 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 38 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 149 | 0.190 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 201 | 0.190 |
Why?
|
| Cloud Computing | 1 | 2021 | 13 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 70 | 0.180 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2022 | 116 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 253 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 55 | 0.180 |
Why?
|
| Neck Dissection | 1 | 2021 | 67 | 0.180 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.180 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 45 | 0.180 |
Why?
|
| Neoplasms, Experimental | 2 | 2020 | 270 | 0.180 |
Why?
|
| Endogenous Retroviruses | 1 | 2020 | 10 | 0.180 |
Why?
|
| Acetophenones | 1 | 2020 | 27 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.170 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 179 | 0.170 |
Why?
|
| Recombinational DNA Repair | 1 | 2020 | 9 | 0.170 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 26 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 598 | 0.170 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 20 | 0.170 |
Why?
|
| 4-1BB Ligand | 1 | 2020 | 3 | 0.170 |
Why?
|
| Mitochondria | 1 | 2024 | 598 | 0.170 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2020 | 17 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2021 | 187 | 0.170 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 103 | 0.170 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 88 | 0.170 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2024 | 692 | 0.170 |
Why?
|
| Actomyosin | 1 | 2020 | 47 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 371 | 0.170 |
Why?
|
| Software | 1 | 2024 | 673 | 0.160 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 28 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 530 | 0.160 |
Why?
|
| Naphthalenes | 1 | 2019 | 40 | 0.160 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 453 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 208 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 496 | 0.160 |
Why?
|
| Quinolines | 1 | 2019 | 88 | 0.160 |
Why?
|
| Mitosis | 2 | 2017 | 154 | 0.160 |
Why?
|
| Cytoskeleton | 1 | 2020 | 202 | 0.160 |
Why?
|
| Point Mutation | 1 | 2019 | 245 | 0.150 |
Why?
|
| Cell Adhesion | 2 | 2020 | 431 | 0.150 |
Why?
|
| Olfactory Mucosa | 1 | 2018 | 33 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 30 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 59 | 0.150 |
Why?
|
| Treatment Outcome | 7 | 2022 | 8725 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2023 | 9675 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 164 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2018 | 60 | 0.150 |
Why?
|
| Indoles | 1 | 2020 | 306 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 176 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 112 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 132 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 786 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 678 | 0.140 |
Why?
|
| Students, Medical | 1 | 2023 | 433 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2023 | 4466 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 183 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 92 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 469 | 0.140 |
Why?
|
| Logistic Models | 1 | 2020 | 1239 | 0.130 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2016 | 17 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2020 | 552 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2018 | 476 | 0.130 |
Why?
|
| Gossypol | 1 | 2016 | 5 | 0.130 |
Why?
|
| Trans-Activators | 1 | 2019 | 441 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 538 | 0.130 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 401 | 0.130 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 52 | 0.130 |
Why?
|
| Time Factors | 4 | 2020 | 5426 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2017 | 232 | 0.130 |
Why?
|
| Adult | 12 | 2025 | 27494 | 0.130 |
Why?
|
| Retinal Dehydrogenase | 1 | 2015 | 7 | 0.120 |
Why?
|
| Taxoids | 1 | 2016 | 126 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2016 | 119 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 38 | 0.120 |
Why?
|
| Biostatistics | 1 | 2015 | 21 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2443 | 0.120 |
Why?
|
| Cell Separation | 1 | 2016 | 201 | 0.120 |
Why?
|
| Cell Division | 1 | 2016 | 700 | 0.120 |
Why?
|
| Risk Factors | 3 | 2021 | 5697 | 0.120 |
Why?
|
| Aniline Compounds | 1 | 2015 | 61 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 234 | 0.120 |
Why?
|
| Isoenzymes | 1 | 2015 | 277 | 0.120 |
Why?
|
| Models, Theoretical | 3 | 2023 | 496 | 0.110 |
Why?
|
| Microbiota | 1 | 2020 | 413 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 797 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2021 | 772 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1051 | 0.110 |
Why?
|
| United States | 3 | 2022 | 7338 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 775 | 0.110 |
Why?
|
| Drug Synergism | 3 | 2020 | 312 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2021 | 2366 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 462 | 0.110 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 398 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 276 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2015 | 328 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 1179 | 0.100 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 15 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2020 | 828 | 0.090 |
Why?
|
| BRCA2 Protein | 2 | 2023 | 165 | 0.090 |
Why?
|
| BRCA1 Protein | 2 | 2023 | 207 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 127 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 1731 | 0.080 |
Why?
|
| Apoptosis | 4 | 2018 | 1742 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 67 | 0.080 |
Why?
|
| Methylmercury Compounds | 1 | 2009 | 3 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 498 | 0.080 |
Why?
|
| Hair | 1 | 2009 | 56 | 0.080 |
Why?
|
| Milk, Human | 1 | 2009 | 46 | 0.080 |
Why?
|
| Intelligence | 1 | 2009 | 71 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 377 | 0.080 |
Why?
|
| Phenotype | 3 | 2021 | 2497 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6905 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 1773 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 868 | 0.070 |
Why?
|
| Biomarkers | 2 | 2023 | 1846 | 0.060 |
Why?
|
| Cytokines | 2 | 2021 | 840 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2020 | 475 | 0.060 |
Why?
|
| Cell Survival | 2 | 2018 | 1008 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 865 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1937 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2018 | 513 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1764 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2790 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 1742 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2024 | 22 | 0.060 |
Why?
|
| Perforin | 1 | 2023 | 55 | 0.050 |
Why?
|
| Phthalazines | 1 | 2023 | 47 | 0.050 |
Why?
|
| European Union | 1 | 2023 | 8 | 0.050 |
Why?
|
| Pathology, Oral | 1 | 2023 | 5 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 169 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 35 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 295 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 485 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2023 | 110 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 97 | 0.050 |
Why?
|
| Adolescent | 3 | 2022 | 9493 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 140 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 125 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 134 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2023 | 137 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 291 | 0.050 |
Why?
|
| Switzerland | 1 | 2021 | 18 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 33 | 0.050 |
Why?
|
| Histological Techniques | 1 | 2021 | 36 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2022 | 132 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 268 | 0.050 |
Why?
|
| Germany | 1 | 2021 | 74 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 109 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 44 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 282 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 173 | 0.040 |
Why?
|
| Japan | 1 | 2021 | 306 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 151 | 0.040 |
Why?
|
| Shoulder | 1 | 2021 | 43 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2022 | 549 | 0.040 |
Why?
|
| Hematoxylin | 1 | 2020 | 6 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 11 | 0.040 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2020 | 2 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 23 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 24 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 35 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2020 | 33 | 0.040 |
Why?
|
| Oncogenic Viruses | 1 | 2020 | 4 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2020 | 159 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 15 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2020 | 91 | 0.040 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 22 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 99 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 293 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 177 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 37 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 569 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 199 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1193 | 0.040 |
Why?
|
| Gastritis | 1 | 2020 | 36 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2020 | 83 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 103 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 68 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2020 | 81 | 0.040 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 48 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 81 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 800 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 137 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 652 | 0.040 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2018 | 9 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2020 | 149 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2018 | 17 | 0.040 |
Why?
|
| Probiotics | 1 | 2020 | 90 | 0.040 |
Why?
|
| Symbiosis | 1 | 2020 | 131 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 80 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 124 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 64 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 104 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2018 | 88 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 358 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 273 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 6615 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 165 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Estrogens | 1 | 2018 | 200 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 786 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 238 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 22 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1108 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 291 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2020 | 498 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 673 | 0.030 |
Why?
|
| Actins | 1 | 2020 | 470 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1589 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1148 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 10 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 220 | 0.030 |
Why?
|
| Breast | 1 | 2018 | 289 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 810 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2018 | 473 | 0.030 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cell Movement | 1 | 2020 | 797 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1509 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 120 | 0.030 |
Why?
|
| Spiro Compounds | 1 | 2016 | 26 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 127 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2017 | 70 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2016 | 68 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1898 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 122 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 119 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1336 | 0.030 |
Why?
|
| G1 Phase | 1 | 2016 | 67 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 235 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 167 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2015 | 6 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 107 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1239 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 624 | 0.030 |
Why?
|
| Bacteria | 1 | 2020 | 499 | 0.030 |
Why?
|
| Neprilysin | 1 | 2015 | 41 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2899 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 171 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 950 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1916 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 109 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 172 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 90 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 1128 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 472 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 164 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 327 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 680 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1512 | 0.030 |
Why?
|
| Publishing | 1 | 2015 | 92 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 381 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1804 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1246 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 441 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 704 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3356 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 167 | 0.030 |
Why?
|
| Child | 2 | 2019 | 7323 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 1111 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 328 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1924 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 445 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 899 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1142 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1654 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 556 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1590 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1721 | 0.020 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2011 | 9 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1399 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2388 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 382 | 0.020 |
Why?
|
| Seychelles | 1 | 2009 | 2 | 0.020 |
Why?
|
| Seafood | 1 | 2009 | 10 | 0.020 |
Why?
|
| Mercury | 1 | 2009 | 12 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2009 | 60 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 1768 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1080 | 0.020 |
Why?
|
| Aging | 1 | 2009 | 733 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 3211 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 3812 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2337 | 0.010 |
Why?
|